Literature DB >> 17560276

Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection.

Brad R Rosenberg1, F Nina Papavasiliou.   

Abstract

As the primary effector of immunoglobulin somatic hypermutation (SHM) and class switch recombination (CSR), activation-induced cytidine deaminase (AID) serves an important function in the adaptive immune response. Recent advances have demonstrated that AID and a group of closely related cytidine deaminases, the APOBEC3 proteins, also act in the innate host response to viral infection. Antiviral activity was first attributed to APOBEC3G as a potent inhibitor of HIV. It is now apparent that the targets of the APOBEC3 proteins extend beyond HIV, with family members acting against a wide variety of viruses as well as host-encoded retrotransposable genetic elements. Although it appears to function through a different mechanism, AID also possesses antiviral properties. Independent of its antibody diversification functions, AID protects against transformation by Abelson murine leukemia virus (Ab-MLV), an oncogenic retrovirus. Additionally, AID has been implicated in the host response to other pathogenic viruses. These emerging roles for the AID/APOBEC cytidine deaminases in viral infection suggest an intriguing evolutionary connection of innate and adaptive immune mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560276     DOI: 10.1016/S0065-2776(06)94007-3

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  24 in total

1.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

Review 2.  The curious chemical biology of cytosine: deamination, methylation, and oxidation as modulators of genomic potential.

Authors:  Christopher S Nabel; Sara A Manning; Rahul M Kohli
Journal:  ACS Chem Biol       Date:  2011-10-31       Impact factor: 5.100

3.  Genetic variants and prostate cancer risk: candidate replication and exploration of viral restriction genes.

Authors:  Joan P Breyer; Kate M McReynolds; Brian L Yaspan; Kevin M Bradley; William D Dupont; Jeffrey R Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06-30       Impact factor: 4.254

4.  A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase.

Authors:  Rahul M Kohli; Shaun R Abrams; Kiran S Gajula; Robert W Maul; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2009-06-26       Impact factor: 5.157

5.  Evaluation of anti-HIV-1 mutagenic nucleoside analogues.

Authors:  Valérie Vivet-Boudou; Catherine Isel; Yazan El Safadi; Redmond P Smyth; Géraldine Laumond; Christiane Moog; Jean-Christophe Paillart; Roland Marquet
Journal:  J Biol Chem       Date:  2014-11-14       Impact factor: 5.157

6.  Concomitant lethal mutagenesis of human immunodeficiency virus type 1.

Authors:  Michael J Dapp; Colleen M Holtz; Louis M Mansky
Journal:  J Mol Biol       Date:  2012-03-15       Impact factor: 5.469

7.  APOBEC3B and AID have similar nuclear import mechanisms.

Authors:  Lela Lackey; Zachary L Demorest; Allison M Land; Judd F Hultquist; William L Brown; Reuben S Harris
Journal:  J Mol Biol       Date:  2012-03-23       Impact factor: 5.469

Review 8.  Molecular diversity through RNA editing: a balancing act.

Authors:  Sanaz Farajollahi; Stefan Maas
Journal:  Trends Genet       Date:  2010-04-13       Impact factor: 11.639

9.  The interaction between AID and CIB1 is nonessential for antibody gene diversification by gene conversion or class switch recombination.

Authors:  Zachary L Demorest; Donna A MacDuff; William L Brown; Scott G Morham; Leslie V Parise; Reuben S Harris
Journal:  PLoS One       Date:  2010-07-20       Impact factor: 3.240

10.  The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.

Authors:  Nicoletta Casartelli; Florence Guivel-Benhassine; Romain Bouziat; Samantha Brandler; Olivier Schwartz; Arnaud Moris
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.